LDN 193189,
LDN-193189,
LDN193189,
1062368-24-4,
LDN193189,
LDN-193189,
4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline,
UNII-W69H5YQU9O,
LDN 193189,
W69H5YQU9O,
CHEMBL513147,
4-[6-(4-Piperazin-1-Ylphenyl)pyrazolo[1,5-A]pyrimidin-3-Yl]quinoline,
4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline,
LDN 193189 hydrochloride,
4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline,
DM 3189 hydrochloride,
LDN193189 free base,
SCHEMBL456393,
CHEBI:91387,
KS-00000SOA,
AOB3009,
DTXSID30147553,
EX-A424,
BCP01907,
ABP000266,
BDBM50262079,
DM3189,
MFCD17169988,
s2618,
ZINC40880920,
AKOS024464854,
Quinoline, 4-(6-(4-(1-piperazinyl)phenyl)pyrazolo(1,5-a)pyrimidin-3-yl)-,
BCP9000845,
CS-0669,
EX-8677,
RL00282,
SB19315,
NCGC00249389-01,
4CA-0730,
AK163404,
AN-16862,
HY-12071,
QC-11402,
SC-67268,
AB0033774,
FT-0753749,
ST24042993,
X7510,
A25220,
W-5677,
cas:1062368-24-4;LDN193189,
J-514252,
LDN193189(DM3189)/LDN-193189,
BRD-K04853698-003-01-4,
4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyri,
LDN 193189, 1062368-24-4,
LDN 193189; LDN-193189; DM-3189; DM 3189,
4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride,
DM3189;6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine,
cc-233,
LDN193189 HCl,
CDOVNWNANFFLFJ-UHFFFAOYSA-N,
C25H22N6,
1062368-24-4 (free base),
A8324,
A11205,
C554430,
LDN-193189, 98%, a selective BMP signaling inhibitor - 25MG 25mg,
4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride,
6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine,
1435934-00-1,